Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Thierry van den Berg is active.

Publication


Featured researches published by Thierry van den Berg.


Infection and Immunity | 2000

Tuberculosis DNA Vaccine Encoding Ag85A Is Immunogenic and Protective When Administered by Intramuscular Needle Injection but Not by Epidermal Gene Gun Bombardment

Audrey Tanghe; Olivier Denis; Bénédicte Lambrecht; Vinciane Motte; Thierry van den Berg; Kris Huygen

ABSTRACT Immunogenicity and protective efficacy of a DNA vaccine encoding Ag85A from Mycobacterium tuberculosis were compared in BALB/c and C57BL (B6 and B10) mice immunized by intramuscular (i.m.) needle injection or epidermal gene gun (gg) bombardment. In BALB/c mice, gg immunization could induce elevated antibody and cytotoxic T lymphocyte responses with plasmid doses 50-fold lower than those required for i.m. immunization. Interleukin-2 (IL-2) and gamma interferon (IFN-γ) secretion, however, was much lower in gg-immunized than in i.m.-immunized BALB/c mice. On the other hand, C57BL mice reacted only very weakly to gg immunization, whereas elevated Ag85A-specific antibody, IL-2, and IFN-γ responses (significantly higher than in BALB/c mice) were detected following vaccination by the i.m. route. Antibody isotypes were indicative of Th2 activation following gg injection of BALB/c and of Th1 activation following i.m. injection of C57BL mice. Finally, C57BL but not BALB/c mice were protected by i.m. Ag85A DNA immunization against intravenousM. tuberculosis challenge, as measured by reduced numbers of CFU in spleen and lungs, compared to animals vaccinated with control DNA. Gene gun immunization was not effective in either BALB/c or C57BL mice. These results indicate that i.m. DNA vaccination is the method of choice for the induction of protective Th1 type immune responses with the Ag85A tuberculosis DNA vaccine.


Vaccine | 2009

Humoral, cell-mediated and mucosal immunity induced by oculo-nasal vaccination of one-day-old SPF and conventional layer chicks with two different live newcastle disease vaccines.

Fabienne Rauw; Yannick Gardin; Vilmos Palya; Steven Van Borm; Martine Gonze; Sophie Lemaire; Thierry van den Berg; Bénédicte Lambrecht

To further characterize the immune response elicited by two live Newcastle disease vaccines, humoral, cellular and mucosal immunity was evaluated after oculo-nasal vaccination of day-old chickens. The preferential replication sites for each vaccine strain were investigated by screening different tissues using quantitative real-time reverse transcription-polymerase chain reaction (QRRT-PCR). The interference of maternally derived antibody with vaccination was also considered in conventional layer chickens. In SPF chickens, similar humoral immune-response was measured in blood and tears but a differential profile of cell-mediated immunity was observed according to the vaccine strain. The lung-associated humoral immunity was higher with the tracheotropic strain while the enterotropic vaccine induced a more important specific immunity in the digestive tract. The presence of maternally derived antibody in conventional layer chickens limited, if not completely abrogated, their immune responses to vaccination. This study increases our understanding of the protective immune response against Newcastle disease virus (NDV) and provides new useful informations for the development and evaluation of new types of vaccines.


Developmental and Comparative Immunology | 2000

Avian cytokines - the natural approach to therapeutics.

John W. Lowenthal; Bénédicte Lambrecht; Thierry van den Berg; Marion E. Andrew; A.David G Strom; Andrew G. D. Bean

While the effective use of antibiotics for the control of human disease has saved countless lives and has increased life expectancy over the past few decades, there are concerns arising from their usage in livestock. The use of antibiotic feed additives in food production animals has been linked to the emergence in the food chain of multiple drug-resistant bacteria that appear impervious to even the most powerful antimicrobial agents. Furthermore, the use of chemical antimicrobials has led to concerns involving environmental contamination and unwanted residues in food products. The imminent banning of antibiotic usage in livestock feed has intensified the search for environmentally-friendly alternative methods to control disease. Cytokines, as natural mediators and regulators of the immune response, offer exciting new alternatives to conventional chemical-based therapeutics. The utilisation of cytokines is becoming more feasible, particularly in poultry, with the recent cloning of a number of avian cytokine genes. Chickens offer an attractive small animal model system with which to study the effectiveness of cytokine therapy in the control of disease in intensive livestock. In this report we will review the status of avian cytokines and focus on our recent studies involving the therapeutic potential of chicken interferon gamma (ChIFN-gamma) as a vaccine adjuvant and a growth promoter.


Molecular Therapy | 2011

Intranasal DNA Vaccination Induces Potent Mucosal and Systemic Immune Responses and Cross-protective Immunity Against Influenza Viruses

Lea Torrieri-Dramard; Bénédicte Lambrecht; Helena Lage Ferreira; Thierry van den Berg; David Klatzmann; Bertrand Bellier

The induction of potent virus-specific immune responses at mucosal surfaces where virus transmission occurs is a major challenge for vaccination strategies. In the case of influenza vaccination, this has been achieved only by intranasal delivery of live-attenuated vaccines that otherwise pose safety problems. Here, we demonstrate that potent mucosal and systemic immune responses, both cellular and humoral, are induced by intranasal immunization using formulated DNA. We show that formulation with the DNA carrier polyethylenimine (PEI) improved by a 1,000-fold the efficiency of gene transfer in the respiratory track following intranasal administration of luciferase-coding DNA. Using PEI formulation, intranasal vaccination with DNA-encoding hemagglutinin (HA) from influenza A H5N1 or (H1N1)2009 viruses induced high levels of HA-specific immunoglobulin A (IgA) antibodies that were detected in bronchoalveolar lavages (BALs) and the serum. No mucosal responses could be detected after parenteral or intranasal immunization with naked-DNA. Furthermore, intranasal DNA vaccination with HA from a given H5N1 virus elicited full protection against the parental strain and partial cross-protection against a distinct highly pathogenic H5N1 strain that could be improved by adding neuraminidase (NA) DNA plasmids. Our observations warrant further investigation of intranasal DNA as an effective vaccination route.


Vaccine | 2010

Improved vaccination against Newcastle disease by an in ovo recombinant HVT-ND combined with an adjuvanted live vaccine at day-old.

Fabienne Rauw; Yannick Gardin; Vilmos Palya; Sofia Anbari; Sophie Lemaire; M. Boschmans; Thierry van den Berg; Bénédicte Lambrecht

The continuous outbreaks of fatal Newcastle disease (ND) in commercial poultry flocks demonstrate that current vaccination strategies are not fully efficacious and should be improved by new generation of vaccines. In this context, maternally immune conventional layer chickens were vaccinated in ovo with a turkey herpesvirus recombinant expressing the fusion (F) gene of NDV (rHVT-ND) and/or at day-old with an apathogenic enterotropic live ND vaccine co-administrated or not with chitosan by oculo-nasal route. The induced vaccinal immune responses and conferred protection against a challenge with a circulating NDV velogenic viscerotropic strain were evaluated. The innovative rHVT-ND/live ND-chitosan vaccination regimen provided the best protection against mortality and morbidity as well as the strongest reduction of virus shedding that could be related to the higher measured cellular immune response and digestive antibody-mediated immunity.


Veterinary Microbiology | 2013

Diagnosis of Schmallenberg virus infection in malformed lambs and calves and first indications for virus clearance in the fetus.

Nick De Regge; Thierry van den Berg; Laura Georges; Brigitte Cay

Since mid-December 2011, samples from malformed lambs and calves are sent to CODA-CERVA in Belgium for diagnosis of Schmallenberg virus (SBV), a novel Orthobunyavirus that was first detected by researchers of the Friedrich-Loeffler-Institut (FLI, Germany) in German cattle in autumn 2011 and was later shown to be involved in congenital malformations in lambs, goat kids and calves. Surprisingly, by making use of real time RT-PCR (rRT-PCR) assays developed by the FLI, presence of SBV RNA could only be confirmed in part of the SBV suspected newborns examined. To investigate possible causes for non-confirmation by rRT-PCR, a comparative analysis between different organs and tissues (cerebrum, cerebellum, brain stem, spinal cord, thymus, spleen, lymph nodes, meconium) originating from respectively 90 and 81 malformed lambs and calves was undertaken. Furthermore, thoracic fluids of respectively 55 malformed lambs and calves were examined by a virus neutralization test (VNT) to evaluate the presence of neutralizing anti-SBV antibodies in these animals. Our results show that among the different organs tested by rRT-PCR, brain stem material is the most appropriate tissue for SBV detection while it could also be detected in all other tissues but to a more variable degree. The VNT test showed that 95% of the malformed lambs were positive for anti-SBV neutralizing antibodies while this was only the case for 44% of malformed calves. These immunological data suggest that a humoral immune response could assist in the clearance of SBV from the fetus during gestation and that SBV specific antibody testing should be considered together with rRT-PCR analysis for confirmation of SBV infection.


Veterinary Immunology and Immunopathology | 2010

The positive adjuvant effect of chitosan on antigen-specific cell-mediated immunity after chickens vaccination with live Newcastle disease vaccine.

Fabienne Rauw; Yannick Gardin; Vilmos Palya; Sofia Anbari; Martine Gonze; Sophie Lemaire; Thierry van den Berg; Bénédicte Lambrecht

The development of safe, novel strong adjuvants is necessary to maximize the efficacy of and the immune response induced by new and/or available vaccines administered through the mucosal route to chickens. Chitosan is a non-toxic, biocompatible, biodegradable and natural polysaccharide derived from the exoskeleton of crustaceans and insects. It has been demonstrated to be an effective absorption enhancer to improve mucosal delivery of peptide and protein drugs in human and mice. In poultry, mucosal administration of live vaccine has been already explored with success. However, the effects of the use of the chitosan as adjuvant for mucosal vaccination in birds have not been investigated yet. To this aim, we explored its potential as adjuvant given by oculo-nasal route to one-day-old chickens with live Newcastle disease (ND) vaccine. The immune response has been evaluated during three independent vaccination experiments on specific pathogen free (SPF) chickens. It was shown that chitosan enhanced the antigen-specific cell-mediated immune response in the spleen. New protocols were developed to measure the chicken IFNgamma production after ex vivo antigen-stimulation of peripheral blood and duodenal lamina propria lymphocytes. It was then observed than the peripheral cellular immune response was earlier and stronger, while the local cellular immune response in digestive tract as shorter when chitosan was used as adjuvant. On the other hand, the chitosan had no effect on the systemic, lachrymal and digestive antibody-mediated immunity. This study indicates thus that the chitosan is a cell-promising adjuvant for the mucosal delivery of live vaccine in poultry, by enhancing the Th1 pathway of immunity. However, further investigations are required to explore its mechanism of action and to evaluate the inferred protection.


Developmental and Comparative Immunology | 2013

Infectious Bursal Disease: a complex host-pathogen interaction.

Fiona Ingrao; Fabienne Rauw; Bénédicte Lambrecht; Thierry van den Berg

Infectious Bursal Disease (IBD) is caused by a small, non-enveloped virus, highly resistant in the outside environment. Infectious Bursal Disease Virus (IBDV) targets the chickens immune system in a very comprehensive and complex manner by destroying B lymphocytes, attracting T cells and activating macrophages. As an RNA virus, IBDV has a high mutation rate and may thus give rise to viruses with a modified antigenicity or increased virulence, as emphasized during the last decades. The molecular basis of pathogenicity and the exact cause of clinical disease and death are still poorly understood, as it is not clearly related to the severity of the lesions and the extent of the bursal damage. Recent works however, pointed out the role of an exacerbated innate immune response during the early stage of the infection with upregulated production of promediators that will induce a cytokine storm. In the case of IBDV, immunosuppression is both a direct consequence of the infection of specific target immune cells and an indirect consequence of the interactions occurring in the immune network of the host. Recovery from disease or subclinical infection will be followed by immunosuppression with more serious consequences if the strain is very virulent and infection occurs early in life. Although the immunosuppression caused by IBDV is principally directed towards B-lymphocytes, an effect on cell-mediated immunity (CMI) has also been demonstrated therefore increasing the impact of IBDV on the immunocompetence of the chicken. In addition to its zootechnical impact and its role in the development of secondary infections, it may affect the immune response of the chicken to subsequent vaccinations, essential in all types of intensive farming. Recent progress in the field of avian immunology has allowed a better knowledge of the immunological mechanisms involved in the disease but also should give improved tools for the measurement of immunosuppression in the field situation. Although satisfactory protection may be provided by the induction of high neutralizing antibody titres, interference from parental antibodies with vaccination has become the most important obstacle in the establishment of control programs. In this context, recombinant HVT and immune complex vaccines show promising results.


Emerging Infectious Diseases | 2010

Influenza A strain-dependent pathogenesis in fatal H1N1 and H5N1 subtype infections of mice.

Mutien-Marie Garigliany; Adélite Habyarimana; Bénédicte Lambrecht; Els Van de Paar; Anne Cornet; Thierry van den Berg; Daniel Desmecht

Future treatments may involve customizing treatment to the virus pathotype.


Avian Diseases | 2010

H5N1 high pathogenicity avian influenza virus survival in different types of water.

Katarzyna Domańska-Blicharz; Zenon Minta; Krzysztof Smietanka; Sylvie Marché; Thierry van den Berg

Abstract Persistence of H5N1 high pathogenicity avian influenza virus (HPAIV), isolated during the epidemic in wild birds in Poland in 2006, was evaluated in three water samples derived from the sources known to host wild water birds (city pond, Vistula river mouth, and Baltic Sea). The virus was tested at two concentrations (104 and 106 median tissue culture infective dose per milliliter) and at three temperatures (4 C, 10 C, and 20 C), representing average seasonal temperatures in Poland. All tested water samples were filtered before virus inoculation, and one unfiltered sample (Baltic seawater) was also tested. Infectivity was determined twice a week over a 60-day trial period by microtiter endpoint titration. The persistence of the virus varied considerably depending on its concentration and also on physico-chemical parameters of the water, such as temperature and salinity. Avian influenza virus survival was the highest at 4 C and the lowest at 20 C. Prolonged infectivity of the virus in Baltic seawater (brackish, 7.8 ppt) was also seen. In distilled water, the virus retained its infectivity beyond the 60-day study period. Interestingly, a devastating effect of the unfiltered fraction of seawater was seen as the virus disappeared in this fraction the quickest in all studied combinations; thus, biologic factors may also affect infectivity of HPAIV.

Collaboration


Dive into the Thierry van den Berg's collaboration.

Top Co-Authors

Avatar

Didier Vangeluwe

Royal Belgian Institute of Natural Sciences

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Toon Rosseel

Ghent University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jan Mast

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar

Nathalie Desloges

Institut national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge